Laura FILIPPETTI
Vandœuvre-lès-Nancy, 54500, France
NCT Number: NCT04753762
Coronavirus Disease 2019 (COVID-19) is an infection caused by Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), which affects multiple organ system particularly the lung and heart. Indeed, SARS CoV-2 has various cardiac manifestations which are associated with higher mortality and morbidity. Cardiac involvement, based on elevated levels of myocardial enzymes, have been described in 20 to 30% of COVID-19 infection. However, the physiopathological mechanisms of myocardial injury remains unclear. Main hypothesis include inflammation and cytokine storm, hypercoagulability and vascular thrombosis, inflammation or stress leading to coronary plaque rupture (type I myocardial infarction), supply-demand mismatch and hypoxemia resulting in myocardial damage (type II myocardial infarction) ...
Two patterns can be identified : ischemic or non-ischemic pattern including myocarditis, stress induced cardiomyopathy, thrombo-embolic disease. However, the consequences of myocardial damage after confirmed COVID-19 infection are unknown at medium to long term prognosis.
Data are needed to identify myocardial damage and to guide effective therapies and follow-up (use of ACE inhibitor, beta-blockers, steroids...? ) In this study, the investigators proposed to collect multimodal cardiac imaging including MRI (Magnetic Resonance Imaging) and TTE (Transthoracic echocardiogram) in order to identify and characterize cardiac injury as ischemic or non-ischemic pattern, to better assess risk stratification and to guide effective therapies if necessary.
Looking for future studies?
Notify Me18 year–79 year
All sexes
Observational
Vandœuvre-lès-Nancy, 54500, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 to 4 months after COVID 19 infection
Cardiac TTE imaging is performed during 4 months after COVID-19 infection in patients with suspected cardiac involvement (increase troponin level>50ng/ml or left ventricular dysfunction during hospitalisation for COVID-19 infection) in order to determine tissular characterization, in particular the presence of ischemic or non-ischemic pattern.
Time frame: 1 to 4 months after COVID 19 infection
Cardiac MRI is performed during 4 months after COVID-19 infection in patients with suspected cardiac involvement (increase troponin level>50ng/ml or left ventricular dysfunction during hospitalisation for COVID-19 infection) in order to determine tissular characterization, in particular the presence of ischemic or non-ischemic pattern.
Time frame: 12 +/- 2 months
Cardiac imaging are performed 12 +/-2 months after COVID-19 infection
Time frame: 12+/-2 months
Follow-up at 12+/-2 months from COVID-19 infection :
Time frame: 12+/-2 months
Follow-up at 12+/-2 months from COVID-19 infection :
Central Hospital, Nancy, France
Other
Multimodal IMAgery (Echocardiography and Cardiac MRI) Characterization of Cardiac Damage and Severity After COVID-19 Infection
Acronym: IMACovid
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05077332
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Miami, Florida, United States
View Trial DetailsNCT04927442
COVID-19, COVID-19 Virus Disease
Bethesda, Maryland, United States
View Trial DetailsNCT05305508
COVID-19, COVID-19 Virus Disease
Geneva, Switzerland
View Trial DetailsNCT05364268
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Sunrise, Florida, United States
View Trial Details